16:46 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie plans...
21:33 , Jun 7, 2018 |  BC Extra  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie plans...
20:00 , Feb 16, 2018 |  BC Week In Review  |  Company News

Oncologie purchases bavituximab from Avid

Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals. Avid, which transitioned to a contract development and manufacturing organization in January, will receive $8 million upfront...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Interim Phase III data

Interim data from the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC showed that once-weekly IV bavituximab plus docetaxel missed the primary endpoint of improving median...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Phase III discontinued

Peregrine discontinued the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC after a pre-specified interim analysis by an IDMC showed that once-weekly IV bavituximab plus docetaxel...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Peregrine, AstraZeneca deal

The companies expanded an August deal and will evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab in an international Phase II trial in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The original...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Platelet-specific anoctamin 6 (ANO6; TMEM16F)-knockout mouse model of Scott syndrome

Disease models TECHNOLOGY: Transgenics and knockouts A mouse model of platelet aggregation with platelet-specific ANO6 knockout could be used to screen for therapies to treat Scott syndrome, a mild bleeding disorder. In Scott syndrome patients, platelets have...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Peregrine, AstraZeneca deal

The companies partnered to evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab ( MEDI4736) to treat multiple solid tumors. Peregrine will conduct a Phase I/Ib trial. Bavituximab, a chimeric mAb against phosphatidylserine, is in Phase...
07:00 , Sep 28, 2015 |  BioCentury  |  Emerging Company Profile

Microparticle man

RxMP Therapeutics LLC is developing microparticles harvested from red blood cells to mitigate excessive bleeding during surgery or trauma by promoting clotting at sites of bleeding without instigating unwanted coagulation. Available hemostatics used for acute...